Scarica l'app Stockscreener
9.10
1.68%
0.15
Dopo l'orario di chiusura:
9.06
-0.04
-0.44%
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
ETFs Investing in Xeris Biopharma Holdings, Inc. Stocks - TradingView
Xeris Biopharma stock rises 1.62 percent on September 24 - ad-hoc-news.de
XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Chart - ChartMill
Xeris Biopharma (XERS) Edges Higher to $8.20 as Shares Test Upper RangeIPO Entry Watch - dars.gov.et
Xeris Biopharma stock gains on higher targets and August results - ad-hoc-news.de
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A 50% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Xeris Biopharma Holdings stock gains after strong Q2 revenue growth - ad-hoc-news.de
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial StrategySlideshow (NASDAQ:XERS) 2026-09-11 - Seeking Alpha
XERS Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
Oppenheimer reiterates Xeris Pharmaceuticals stock rating on XP-8121 outlook - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - cnn.com
Xeris Biopharma Holdings, Inc. (XERS) stock price, news, quote and history - uk.finance.yahoo.com
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript - GuruFocus
XERS Looks 54.7% Overvalued on GF Value™ as Clinical Update Appr - GuruFocus
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - Stock Titan
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - Stock Titan
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism - businesswire.com
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com South Africa
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock By Investing.com - Investing.com India
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares - Investing.com
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Canada
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - kalkinemedia.com
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma stock holds at $8.48 after earnings miss - ad-hoc-news.de
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
Xeris (XERS) Earnings Report: Profit Per Share Falls Below Its Benchmark in the Available Record; Price Reaction - vinanet.vn
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move - vinanet.vn
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move: Shares Move Lower 0.79% on the DayDiluted EPS Report - dars.gov.et
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Sahm
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS Q2 2026 Earnings: Steep EPS Miss Weighs on SharesFinancial Summary - vinanet.vn
XERS|Xeris Biopharma Holdings Inc|Price:8.500|Chg%:-0.100 - TradingKey
XERS Q2 2026 Earnings: Significant EPS Miss Weighs on SharesRevenue Per Share - Vinanet
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):